Study explains why certain immunotherapies don't always work as predicted | MIT News | Massachusetts Institute of Technology

An MIT study reveals a possible explanation for why checkpoint blockade inhibitors don’t work well for some patients whose tumors have a high mutational burden.

Related Keywords

Peter Westcott ,Tyler Jacks ,Isidro Cortes Ciriano ,Davidh Koch ,Koch Institute ,Howard Hughes Medical Institute ,European Bioinformatics Institute ,Us National Cancer Institute ,Koch Institute For Cancer Research ,Cold Spring Harbor Laboratory ,Bioinformatics Institute ,Koch Institute Support ,Cancer Institute ,Damon Runyon Fellowship ,Tumor Mutational Burden ,Intratumoral Heterogeneity ,Checkpoint Blockade Inhibitors ,Ancer Immunotherapy ,Pd 1 ,Lonal Mutations ,Ubclonal Mutations ,